Jerome Hruska, DO
Pulmonary Disease · Las Vegas, NVNPI 1033430962
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (60.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 93.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $48,130 and has fallen 74.4% since, to $12,311 in 2025. Among pulmonary disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $292.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$67K
- Olympus Corporation Of The Americas$2K
- ERBE USA Inc$505
- Regeneron Healthcare Solutions, Inc.$417
- Pulmonx Corporation$334
- Acera Surgical, Inc.$262
- plus $1K from 16 others
What the payments were for
- Consulting fees$2000%
- Speaking & faculty fees$5,3007%
- Travel & lodging$12,35917%
- Food & beverage$10,95615%
- Education$43,17460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 172 | $67,309 |
| Olympus Corporation Of The Americas | 15 | $1,667 |
| ERBE USA Inc | 2 | $505 |
| Regeneron Healthcare Solutions, Inc. | 12 | $417 |
| Pulmonx Corporation | 3 | $334 |
| Acera Surgical, Inc. | 2 | $262 |
| Olympus America Inc. | 3 | $202 |
| Bayer | 1 | $200 |
| Galvanize Therapeutics, Inc | 2 | $194 |
| AstraZeneca | 6 | $146 |
| GSK | 7 | $120 |
| Boston Scientific | 2 | $114 |
| Amgen | 5 | $108 |
| Boehringer Ingelheim | 3 | $104 |
| Verona Pharma, Inc. | 4 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Sanofi | 1 | $32 |
| Grifols USA, LLC | 1 | $30 |
| United Therapeutics Corporation | 1 | $23 |
| Novartis | 1 | $19 |
| Merck | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$56,050
- ION$3,000
- DAVINCI XI$3,000
- DA VINCI SP$2,300
- Spiration Valve System$729
- Cryo2technology$465
- CHARTIS CATHETER$309
- ZEPHYR DELIVERY CATHETER$309
- ZEPHYR ENDOBRONCHIAL VALVE$309
- PULMONX CHARTIS TABLET CONSOLE$309
- Restrata Wound Matrix$262
- SINGLE USE SUCTION VALVE (Sterile)$208
- Adempas$200
- ALIYA SYSTEM$166
- DUPIXENT$106
- Watchman$100
How this compares
$71,989 in reported general payments places this provider in the 90th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 13 | $163,703 |
| Dupixent PenDupilumab | 34 | $139,511 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $135,276 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $55,584 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $38,332 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $29,719 |
| Spiriva RespimatTiotropium Bromide | 28 | $17,933 |
| XareltoRivaroxaban | 16 | $13,542 |
| EliquisApixaban | 11 | $12,094 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,141 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,991 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $2,805 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,790 |
| Sildenafil Citrate | 14 | $812 |
| Roflumilast | 22 | $572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $120 | $173,608208 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $146 | $58,37475 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $104 | $47,65264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Las Vegas
- Arthur RomeroLas Vegas$310K
- Lloyd DelmundoLas Vegas$150K
- Naresh SinghLas Vegas$111K
- Abhishek KumarLas Vegas$74K
- Vishisht MehtaLas Vegas$22K
- Kamran KhanLas Vegas$17K
- John WojcikLas Vegas$14K
- Walter WilloughbyLas Vegas$10K
- Robert LampertLas Vegas$8K
- Rachakonda PrabhuLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.